BEAM-101 seems to be competitive with approved sickle cell treatments, William Blair analysts said in a note to investors, ...

BEAM-101 is an ex vivo genetic therapy delivered as part of an autologous haematopoietic stem cell transplant (HSCT) after a ...

Beam Therapeutics enrolls 35 patients in BEACON trial for BEAM-101 in sickle cell disease, with promising early safety and ...

The death, which investigators linked to a preparatory chemo treatment rather than Beam's medicine, highlights the risks of ...

Beam Therapeutics gave an initial look at the first handful of patients who received its experimental gene-edited treatment ...

Beam Therapeutics (NASDAQ:BEAM) fell sharply in the morning hours Tuesday after multiple media reports indicated that a patient has died following the administration of the company's experimental gene ...

BMO Capital says the first-ever clinical data from Beam Therapeutics (BEAM)’ base editing platform in sickle cell disease, or SCD, ...

The patient died four months after BEAM-101 infusion “due to respiratory failure that was determined by the investigator to ...

Veterans Day 2024 has revived interest in what was at one time Gerstner Field, one of the largest of the 28 Aviation Signal ...

Initial Clinical Data for BEAM-101 and Preclinical Non-human Primate Data for ESCAPE Accepted for Presentation at American Society of Hematology ...

Analysts estimate that Beam Therapeutics will report an earnings per share (EPS) of $-1.16. The announcement from Beam Therapeutics is eagerly anticipated, with investors seeking news of surpassing ...

To accelerate its production, Israel recently invested over USD 500 million in contracts with local defense companies, Rafael ...